114
Participants
Start Date
October 27, 2021
Primary Completion Date
October 31, 2027
Study Completion Date
October 31, 2027
Cyclophosphamide
Lymphodepleting chemotherapy administered intravenously
Fludarabine
Lymphodepleting chemotherapy administered intravenously
KITE-363
A single infusion of CAR-transduced autologous T cells administered intravenously
KITE-753
A single infusion of CAR-transduced autologous T cells administered intravenously
RECRUITING
Royal North Shore Hospital, St Leonards
RECRUITING
Columbia University Irving Medical Center, New York
RECRUITING
University of Rochester Medical Center, Rochester
RECRUITING
University of MD, Greenebaum Comprehensive Cancer Center, Baltimore
RECRUITING
Virginia Oncology Associates, Norfolk
RECRUITING
Northside Hospital, Atlanta
RECRUITING
The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus
RECRUITING
The University of Texas, MD Anderson Cancer Center, Houston
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
RECRUITING
Stanford Cancer Institute, Stanford
RECRUITING
Universitatsklinikum Wurzburg, Würzburg
RECRUITING
Hackensack University Medical Center, Hackensack
RECRUITING
Academisch Medisch Centrum, Amsterdam
RECRUITING
King's College Hospital, London
Kite, A Gilead Company
INDUSTRY